Bruker Corporation logo
Bruker Corporation BRKR
$ 57.08 3.84%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Bruker Corporation Income Statement 2025-2008 | BRKR

Brief overview of profit and loss at Bruker Corporation

The conclusions below are based on five years of reported results. Bruker Corporation reported revenue of $2 billion in 2020 and $3.4 billion by 2025. The total change was +72.9%, with a CAGR of approximately 11.6%. The pace indicates confident and sustained business growth.

The five-year change in gross profit reached +67.9%: from $940 million to $1.6 billion. Revenue and direct costs changed at similar rates. At the margin level, the figure shifted from 47.3% to 45.9%. The gross margin stayed within a similar range.

EBITDA changed from 342 million dollars to 288 million dollars (−15.6%). Operating performance weakened relative to revenue. EBITDA margin moved from 17.2% to 8.4%. Operating return per unit of revenue declined.

The final result was $158 million initially and −$8.3 million in the final year. The move from profit to loss indicates a material deterioration in final efficiency.

The five-year change in capitalization reached −36.9%: from $8.8 billion to $5.6 billion. Capitalization lags the underlying business improvement.

What the figures show

The indicators point to a weaker financial profile. The financial profile benefits from revenue expansion. The main areas of concern are a weaker final result, weaker gross profitability and weaker operating efficiency. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Bruker Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

5.58 B 6.9 B 12.6 B 12.8 K 10.1 K 8.84 B 7.85 B 5.51 B 5.59 B 3.73 B 3.76 B 3.16 B 3.45 B 2.78 B 2.31 B 2 B 1.14 B -

Shares

152 M 149 M 146 M 149 151 153 M 155 M 156 M 158 M 161 M 168 M 168 M 166 M 166 M 165 M 164 M 164 M -

Historical Prices

36.7 46.3 86.2 86.2 66.6 57.8 49.2 34.7 35.1 23.2 21.8 18.4 19.8 16.4 13.8 12.2 6.99 11.6

Net Income

-8.3 M 114 M 428 M 298 M 277 M 158 M 197 M 180 M 78.6 M 154 M 102 M 56.7 M 80.1 M 77.5 M 92.3 M 95.4 M 81 M -

Revenue

3.44 B 3.37 B 2.96 B 2.53 B 2.42 B 1.99 B 2.07 B 1.9 B 1.77 B 1.61 B 1.62 B 1.81 B 1.84 B 1.79 B 1.65 B 1.3 B 1.11 B -

Cost of Revenue

1.86 B 1.72 B 1.45 B 1.22 B 1.21 B 1.05 B 1.08 B 996 M 950 M 866 M 915 M 1.05 B 1.03 B 962 M 899 M 701 M 597 M -

Gross Profit

1.58 B 1.65 B 1.51 B 1.31 B 1.21 B 940 M 995 M 900 M 813 M 742 M 709 M 763 M 805 M 831 M 752 M 604 M 518 M -

Operating Income

68.2 M 253 M 437 M 433 M 413 M 248 M 301 M 262 M 220 M 182 M 146 M 105 M 148 M 156 M 156 M 156 M 137 M -

Interest Expense

-46.2 M -38.2 M 16.4 M 16.1 M 14.3 M 14.4 M 16 M 12.6 M 15.4 M 13.2 M 13 M 13.3 M 13.4 M 14.3 M 7.3 M 5.6 M 7.5 M -

EBITDA

288 M 437 M 552 M 522 M 502 M 342 M 375 M 334 M 294 M 251 M 204 M 177 M 232 M 242 M 172 M 192 M 166 M -

Operating Expenses

1.51 B 1.4 B 1.08 B 873 M 796 M 678 M 696 M 631 M 583 M 546 M 557 M 646 M 634 M 649 M 584 M 448 M 381 M -

General and Administrative Expenses

946 M 894 M 729 M 607 M 561 M 478 M 505 M 453 M 416 M 390 M 403 M 451 M 444 M 454 M 407 M 301 M 254 M -

All numbers in USD currency

Quarterly Income Statement Bruker Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

152 M 152 M 152 M 152 M 152 152 M 152 M 147 145 145 M 147 147 147 147 M 148 149 150 151 M 151 151 M 152 152 M 153 M 154 M 154 M 154 M 154 M 156 M 157 M 157 M 156 M 156 M 156 M 156 M 158 M 160 M 160 M 160 M 161 M 161 M 163 M 165 M 168 M 168 M 168 M 169 M 168 M 168 M 167 M 168 M 167 M 167 M 166 M 167 M 166 M 166 M 166 M 166 M 166 M 165 M 165 M

Net Income

-52 M 14.4 M -59.6 M 7.6 M 17.4 M - 40.9 M 7.6 M 50.9 M - 88.1 M 57.1 M 76.5 M - 88.1 M 49.5 M 61.6 M - 87.1 M 57.6 M 56.7 M - 54.3 M 24.1 M 10.5 M 68.6 M 61.3 M 36.5 M 30.8 M 78.1 M 43.4 M 31.2 M 27 M -3.4 M 37 M 23.4 M 21.6 M 69 M 46.5 M 14.5 M 23.6 M 61.4 M 11.8 M 21.9 M 6.5 M 26.1 M 5.5 M 16.4 M 8.7 M 35.2 M 16.6 M 22.9 M 5.4 M 12.8 M 39.7 M 9.9 M 15.1 M 39.1 M 19.8 M 22.1 M 11.3 M

Revenue

838 M 823 M 860 M 797 M 801 M - 864 M 801 M 722 M - 743 M 682 M 685 M - 639 M 588 M 595 M - 609 M 571 M 555 M - 511 M 425 M 424 M 600 M 521 M 490 M 461 M 554 M 467 M 444 M 432 M 530 M 436 M 415 M 385 M 470 M 394 M 372 M 375 M 478 M 396 M 396 M 354 M 508 M 420 M 457 M 424 M 552 M 439 M 455 M 393 M 517 M 448 M 421 M 406 M 475 M 418 M 401 M 357 M

Cost of Revenue

422 M 444 M 481 M 440 M 410 M - 446 M 416 M 369 M - 360 M 341 M 326 M - 304 M 290 M 289 M - 300 M 290 M 276 M - 263 M 238 M 232 M - 267 M 260 M 247 M - 244 M 238 M 232 M - 237 M 230 M 208 M - 209 M 202 M 209 M - 229 M 227 M 193 M - 252 M 257 M 244 M - 246 M 253 M 219 M - 238 M 232 M 215 M - 229 M 218 M 195 M

Gross Profit

416 M 380 M 379 M 358 M 391 M - 419 M 385 M 353 M - 383 M 340 M 360 M - 335 M 298 M 306 M - 309 M 281 M 279 M - 248 M 186 M 192 M 296 M 254 M 230 M 215 M 273 M 223 M 205 M 199 M 256 M 199 M 184 M 176 M 220 M 185 M 170 M 167 M 212 M 168 M 169 M 160 M 216 M 167 M 200 M 180 M 236 M 193 M 202 M 174 M 242 M 210 M 188 M 190 M 218 M 189 M 184 M 162 M

Operating Income

-65.3 M 10.2 M -51.8 M 11.9 M 31.8 M - 68.1 M 48.1 M 64.8 M - 124 M 86.2 M 123 M - 131 M 73.9 M 96.5 M - 113 M 85.6 M 89.1 M - 81.2 M 37.9 M 16.4 M 118 M 87.8 M 53.5 M 41.9 M 106 M 69.1 M 48.8 M 38.1 M 95.3 M 51.3 M 35.3 M 37.6 M 76.9 M 45.9 M 20.4 M 34 M 70.7 M 28.2 M 31.6 M 15.2 M 44.5 M 4.9 M 35.4 M 20.6 M 61 M 31.5 M 43.5 M 12.2 M 39.2 M 60.3 M 22.1 M 34.4 M 53.7 M 37.5 M 38.7 M 25.7 M

Interest Expense

24.6 M 11.7 M -20 M -11.4 M -6.7 M - -12.8 M 15.7 M 6.8 M - 3.9 M 3.9 M 4.2 M - 3.7 M -4 M 4.1 M - - - - - - - - - - -100 K -500 K - 100 K -100 K 600 K - 800 K 2.4 M - - 500 K -400 K -200 K - 500 K - - - 3.2 M 3.1 M 3 M - 3.2 M 3.1 M 3.1 M - 3.4 M 3.5 M 3.3 M - 1.7 M 1.6 M 1.5 M

EBITDA

-7.3 M 68.5 M 3.9 M 68 M 82.2 M - 119 M 73.2 M 99.5 M - 136 M 97.4 M 148 M - 140 M 83.3 M 118 M - 179 M 94.7 M 111 M - 140 M 76.1 M 35.4 M 118 M 145 M 91.9 M 60.9 M 106 M 117 M 81.2 M 53.9 M 95.3 M 99.5 M 66.4 M 52.7 M 76.9 M 86.3 M 47.1 M 47.2 M 70.7 M 68.2 M 58.3 M 28.7 M 44.5 M 52.5 M 65.4 M 35.8 M 61 M 76.9 M 73.7 M 27.4 M 39.2 M 103 M 50.7 M 48 M 53.7 M 76.8 M 64.4 M 37.6 M

Operating Expenses

481 M 370 M 431 M 346 M 359 M - 351 M 336 M 288 M - 258 M 254 M 237 M - 204 M 224 M 210 M - 196 M 195 M 190 M - 167 M 148 M 176 M - 166 M 177 M 173 M - 154 M 156 M 161 M - 148 M 149 M 139 M - 139 M 150 M 133 M - 139 M 138 M 145 M - 162 M 165 M 159 M - 162 M 158 M 162 M - 150 M 166 M 156 M - 152 M 145 M 136 M

General and Administrative Expenses

239 M 242 M 242 M 231 M 225 M - 230 M 221 M 195 M - 178 M 178 M 163 M - 145 M 152 M 146 M - 141 M 135 M 132 M - 115 M 102 M 121 M - 125 M 124 M 120 M - 106 M 111 M 110 M - 103 M 102 M 98.1 M - 96.8 M 101 M 92.7 M - 96.1 M 98.5 M 94.6 M - 108 M 115 M 110 M - 106 M 107 M 107 M - 102 M 111 M 104 M - 102 M 98.2 M 89.3 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Bruker Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.55 0.18 % $ 440 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.8 6.24 % $ 642 M israelIsrael
Electromed Electromed
ELMD
$ 29.6 0.27 % $ 245 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.71 0.69 % $ 12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.32 0.36 % $ 4.38 B britainBritain
LENSAR LENSAR
LNSR
$ 8.3 0.24 % $ 99.3 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.34 0.15 % $ 21.2 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.43 0.93 % $ 2.08 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.33 0.02 % $ 4.35 B usaUSA